A Pivotal Shift in Europe's War on Hepatitis C with New Drug Approval

NORTH CHICAGO, Ill. – June 23, 2026 – In a significant move that could reshape the public health response to a widespread and often invisible disease, the European Commission has approved AbbVie’s MAVIRET for the treatment of acute hepatitis C virus (HCV) infection. This decision makes the oral antiviral therapy the only treatment in the European Union sanctioned for both the acute and chronic stages of the disease, a distinction that promises to dismantle long-standing barriers in the complex system of HCV care.

While a new drug approval is a common headline, this development represents something more fundamental: a recalibration of the infrastructure for fighting a virus that affects over 12 million people in Europe. For years, the fight has been hampered by a system that often waits for the disease to become a chronic, life-altering problem. With this approval, the tools are now in place to shift from a reactive posture to a proactive strategy of early intervention, potentially accelerating Europe's journey toward the ambitious goal of eliminating HCV as a public health threat.

The Silent Epidemic and the Treatment Bottleneck

Hepatitis C is a master of stealth. The blood-borne virus often causes no discernible symptoms during its initial, or acute, phase. This silence allows it to establish a permanent foothold, transitioning to a chronic infection in the majority of untreated individuals. The long-term consequences are severe, leading to progressive liver damage, cirrhosis, cancer, and over 200,000 deaths globally each year. People living with HCV are up to 17 times more likely to develop liver cancer than those without the virus.

Despite the development of highly effective direct-acting antiviral (DAA) therapies over the last decade—drugs that can cure HCV in a matter of weeks—the system of care has struggled to keep pace. A major bottleneck has been the high cost of these revolutionary treatments, which historically led many national health systems to ration access, prioritizing only patients with advanced liver disease. This created a paradoxical and inefficient system: waiting for patients to become critically ill before deploying a cure.

This reactive model left millions with early-stage or undiagnosed infections in a state of limbo, risking further liver damage and unknowingly transmitting the virus to others. The new approval for MAVIRET targets this fundamental flaw by empowering clinicians to act at the earliest possible moment.

Streamlining the System: A Unified Approach to Care

The approval of MAVIRET (glecaprevir/pibrentasvir) for acute HCV provides a crucial tool for simplifying what has been a fragmented care pathway. By authorizing a single, pangenotypic regimen for both stages of the infection, regulators have removed a key administrative and clinical hurdle. A physician who diagnoses HCV no longer needs to differentiate their treatment choice based on the duration of the infection; the same highly effective tool can be deployed immediately.

"People living with HCV infection frequently face delayed treatment, leading to loss to care and onward transmission," said Massimo Puoti, MD, director of the Infectious Diseases Department at Niguarda Hospital in Milan, Italy. "With this approval, healthcare professionals across the European Union now have an approved treatment option to treat patients at the earliest stage of infection, supporting prompt intervention."

The clinical evidence underpinning this shift is robust. The approval was supported by the Phase 3 M20-350 study, which demonstrated that an eight-week course of MAVIRET resulted in a 96.2% cure rate (defined as a sustained virological response, or SVR12) in patients with acute HCV. Crucially, the safety profile was favorable, with no serious adverse reactions related to the treatment and the most common side effects being mild fatigue, headache, and diarrhea.

This creates the potential for a simplified "test-and-treat" model, long advocated by public health experts. Such a system reduces the chance that a patient diagnosed with acute HCV is lost to follow-up while waiting for the infection to either clear on its own—which is rare—or progress to a chronic state. For AbbVie, the strategy appears clear. "Today's European Commission approval of MAVIRET for acute hepatitis C infection enables earlier intervention, aiming to help more people access curative therapy at the time of diagnosis," stated Roopal Thakkar, M.D., the company's chief scientific officer.

Accelerating a Global Health Mandate

This regulatory green light is not just about improving individual patient outcomes; it's about re-engineering the public health response to meet the World Health Organization's goal of eliminating viral hepatitis as a public health threat by 2030. A core pillar of this strategy is preventing new infections, and treating acute cases is one of the most effective ways to do so.

By curing individuals in the acute phase, the pool of infectious carriers is reduced, effectively "turning off the tap" of new chronic cases and curbing community transmission. This is particularly vital for reaching high-risk and often marginalized populations where HCV transmission is most prevalent. The ability to offer a simple, short, and effective cure immediately upon diagnosis could dramatically improve engagement and success rates in these communities.

Furthermore, this move aligns Europe with a growing global consensus. MAVIRET already carries the dual acute and chronic indication in the United States, Canada, Australia, and other nations, signaling a worldwide shift toward this more efficient and proactive treatment paradigm. From a health economics perspective, the logic is compelling: the upfront cost of treating an acute infection is far less than the immense long-term financial and societal burden of managing cirrhosis, liver cancer, and liver transplants.

Reshaping the Market and Overcoming Hurdles

The approval also represents a significant strategic maneuver for AbbVie in the competitive HCV market. For years, the space was dominated by a handful of players, primarily Gilead Sciences. By securing the sole EU approval for both acute and chronic HCV, AbbVie carves out a unique and powerful position for MAVIRET. This distinction could make it the default choice for health systems looking to simplify procurement and streamline clinical guidelines, giving it a distinct advantage over competitors whose drugs are only indicated for chronic infection.

However, the Daniel Howard column is grounded in the realities of how large systems work, and regulatory approval is only the first step on a long and complex road. The true impact of this decision will hinge on the practicalities of access and reimbursement. Each EU member state must now decide, through its own health technology assessment (HTA) bodies, whether and how to fund MAVIRET for this new indication. The historical tension between the high price of DAA therapies and the strained budgets of national health services has not disappeared.

Patient advocacy groups will undoubtedly pressure governments to ensure broad and unrestricted access, arguing that the long-term public health and economic benefits of early treatment far outweigh the immediate costs. The success of this newly streamlined system will depend not on the drug's proven efficacy, but on the political and economic will to deploy it at scale. The tool has been delivered; the challenge now is to ensure it gets into the hands of those who need it, dismantling the final barriers in the global fight against hepatitis C.